Testosterone bounce predicts favorable prognoses for prostate cancer patients treated with degarelix.
Shuhei KamadaShinichi SakamotoRyo KinoshitaXue ZhaoTomohiko KamasakoRyosuke YamaseJunryo RiiShinpei SaitoPae SangjonAkinori TakeiYasutaka YamadaYusuke GotoYusuke ImamuraTaro IguchiAtsushi MizokamiHiroyoshi SuzukiKoichiro AkakuraTomohiko IchikawaPublished in: The Prostate (2024)
The present study revealed that T bounce with cut-off levels of 20 ng/dL is a promising biomarker that predicts OS and CSS for prostate cancer patients treated with degarelix acetate.